Inventor · Saffron Walden, GB

Kim Louise Hirst

15Patents
4h-index
57Co-inventors
59Inventor score

Filing activity: May 11, 2007 → Jan 25, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US7501411B2 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 10 Active
US10544132B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity Chemistry; Metallurgy 7 Active
US7915256B2 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 7 Active
US10526311B2 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity Chemistry; Metallurgy 6 Active
US10981898B2 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity Chemistry; Metallurgy 4 Active
US11261171B1 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity Chemistry; Metallurgy 2 Active
US11603367B2 Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them Chemistry; Metallurgy 2 Active
US7893058B2 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 1 Active
US8148369B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 0 Active
US8178530B2 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 0 Active
US12071429B2 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity Chemistry; Metallurgy 0 Active
US10016439B2 Fused imidazole compounds Chemistry; Metallurgy 0 Active
US12077526B2 Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them Chemistry; Metallurgy 0 Active
US8173656B2 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 0 Active
US9006237B2 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases Human Necessities 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.